Company intelligence / Profile preview

Tenex Therapeutics

Chapel Hill, North Carolina, United Statestenaxthera.com ↗

Ownership: Private
Employees: ~6
Development stage: Phase 3

Overview

Tenax Therapeutics is a late-stage clinical pharmaceutical company focused on novel cardiopulmonary therapies. Its lead programs are in Phase 3 development for pulmonary arterial hypertension and pulmonary hypertension associated with heart failure with preserved ejection fraction. TNX‑201 (oral imatinib) has shown strong efficacy signals in prior studies for PAH, while TNX‑103 (oral levosimendan) is the first therapy to show efficacy in PH-HFpEF patients.

Therapeutic areas: Cardiovascular
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

perfluoro-tert-butylcyclohexane

Partnerships

Orion Corporation

Beyond the preview

Go deeper on Tenex Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tenex Therapeutics.

Explore the full profile